Jump to content

Generalized glucocorticoid resistance

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 04:41, 14 June 2023 (Add: doi-access, page. Removed parameters. | Use this bot. Report bugs. | Suggested by Eastmain | Category:Rare syndromes | #UCB_Category 35/360). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Glucocorticoid resistance is a syndrome characterized by resistance to glucocorticoid hormones such as cortisol.[1] Primary generalized glucocorticoid resistance is also known as Chrousos syndrome and is an extremely rare condition in which a partial resistance to glucocorticoids throughout the entire body occurs.[1] It is caused by mutations in the gene encoding the glucocorticoid receptor.[1] A characteristic of the syndrome is hypothalamic–pituitary–adrenal axis (HPA axis) hyperactivation and adrenal hyperplasia.[1] This in turn results in biochemical signs of hypercortisolism without Cushing's syndrome symptoms (e.g., high levels of cortisol) as well as high levels of adrenal androgens and mineralocorticoids.[1] Presentation may range from asymptomatic to manifestations of androgen excess, mineralocorticoid excess, and neuropsychiatric symptoms such as depression, anxiety, and chronic fatigue.[1] Management of glucocorticoid resistance is limited to symptomatic individuals and is treated with high doses of mineralocorticoid-sparing synthetic corticosteroids such as dexamethasone.[1]

References

  1. ^ a b c d e f g Nicolaides NC, Charmandari E (October 2021). "Primary Generalized Glucocorticoid Resistance and Hypersensitivity Syndromes: A 2021 Update". Int J Mol Sci. 22 (19): 10839. doi:10.3390/ijms221910839. PMC 8509180. PMID 34639183.